FATE vs JBIO

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Aug 15, 2026

FATE

44.8
AI Score
VS
FATE Wins

JBIO

37.9
AI Score

Investment Advisor Scores

FATE

45score
Recommendation
HOLD

JBIO

38score
Recommendation
SELL

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric FATE JBIO Winner
Net Income -136.31M -96.13M JBIO
Operating Income -147.70M -102.36M JBIO
ROE -65.8% -21.9% JBIO
ROA -42.7% -20.4% JBIO
Total Assets 318.94M 472.11M JBIO
Cash 46.63M 107.25M JBIO
Current Ratio 5.79 14.93 JBIO
Free Cash Flow -112.04M -67.93M JBIO

Relative Price Performance (Last 90 Days)

FATE 1M: -7.5% · 3M: +11.0% JBIO 1M: +8.8% · 3M: -9.0%

Current Technical Phase

FATE

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 41

RSI (14): 40.9 · Price: $2.33

JBIO

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 48

RSI (14): 47.5 · Price: $21.34

Fundamentals Snapshot

Metric FATE JBIO
Market Cap
Forward P/E -2.4 -8.0
Trailing P/E
Revenue (TTM)
Revenue Growth 0.1% 0.0%
Gross Margin -12.0%
Operating Margin -15.0% 0.0%
EPS -0.96 -1.01
Dividend Yield

Frequently Asked Questions

Based on our detailed analysis, FATE is currently the stronger investment candidate based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.